Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin

BACKGROUND: The results of the randomized, phase 3 ET743‐SAR‐3007 trial demonstrated that trabectedin had a significantly longer progression‐free survival (PFS) compared with dacarbazine in patients with advanced leiomyosarcoma/liposarcoma after the failure of prior chemotherapy. Patients randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robin L., Maki, Robert G., Patel, Shreyaskumar R., Wang, George, McGowan, Tracy A., Shalaby, Waleed S., Knoblauch, Roland E., von Mehren, Margaret, Demetri, George D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916570/
https://www.ncbi.nlm.nih.gov/pubmed/31503332
http://dx.doi.org/10.1002/cncr.32462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916570/
https://www.ncbi.nlm.nih.gov/pubmed/31503332
http://dx.doi.org/10.1002/cncr.32462

Ejemplares similares